Clinical Research Directory

Inclusion Criteria: * Adults ≥18 years; * Living with HIV-1; * With pVL \<50 copies/mL for at least 24 months; * Under stable three-drug regimen including 2 NRTIs + 1 NNRTI or 1 INSTI or 1 boosted PI for at least 12 months; * Affiliated to the French Social Insurance; * Who have given their written consent to participate in the study Exclusion Criteria: * HIV-2 co-infection; * Co-infection with hepatitis B virus (positive HBsAg and/or positive anti-HBc antibody with negative anti-HBs antibody); * Documented resistance mutation or association of resistance mutations, associated with partial or full resistance to doravirine, dolutegravir or lamivudine; * At least one resistance genotype is mandatory to include the patient: * If there was no virological failure under NRTI, NNRTI and INSTI in the past: * Pretherapeutic HIV-RNA genotype, * OR, in case of no available HIV-RNA genotype, genotype on proviral HIV-DNA to performed before inclusion, * In case of virological failure under NRTI, NNRTI and INSTI in the past: * HIV-RNA genotype at time of virological failure, * OR, in case of no available HIV-RNA genotype at time of failure, genotype on proviral HIV-DNA to performed before inclusion to be sure that the virus is fully sensitive to the study treatments, * Past virological failure is defined as: 2 consecutive pVL ≥50 copies/mL or one pVL ≥200 copies/mL, * Resistance genotypes will be interpretated with the last available ANRS algorithm. * Glomerular filtration rate \<50 mL/min (CKD-EPI formula); * Comedications leading to drug-drug interaction with one of the 3 study drugs (cf. detailed protocol); * Pregnant or breastfeeding women, and women with age to be pregnant but refusing effective contraception, whether or not a desire for pregnancy is expressed; * Any clinal condition limiting the participation in a clinical trial: Immunocompromised conditions including active cancer or hematological malignancy, organ transplant or with transplant rejection within the last 6 months, immunosuppressive therapy, or other condition that in the opinion of the investigator could cause impaired host immunity * Protected adults (persons under legal guardianship or under "sauvegarde de justice" (judicial protection due to temporarily and slightly diminished mental or physical faculties)